Aravive, Inc. Form 8-K October 30, 2018

# **UNITED STATES**

# SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

#### FORM 8-K

#### **CURRENT REPORT**

#### PURSUANT TO SECTION 13 OR 15(d)

## **OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): October 30, 2018

## ARAVIVE, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction 001-36361 (Commission 26-4106690 (IRS Employer

of incorporation)

File Number) LyondellBasell Tower **Identification Number**)

Edgar Filing: Aravive, Inc. - Form 8-K

### 1221 McKinney Street, Suite 3200

#### Houston, Texas 77010

#### (Address of principal executive offices, including zip code)

#### (936) 355-1910

#### (Registrant s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

#### Item 7.01. Regulation FD Disclosure.

Aravive, Inc. (the Company ) prepared the Aravive Corporate Presentation attached as Exhibit 99.1 to this Current Report on Form 8-K (the Investor Presentation ), which will be presented by the Company s management during investor meetings beginning on October 30, 2018. Information from this Investor Presentation may also be used by the management of the Company in future meetings regarding the Company.

The information contained in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liabilities of that section. The information contained in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

# Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

ExhibitDescription99.1Investor Presentation

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

# Aravive, Inc.

Dated: October 30, 2018

By: /s/ Jay P. Shepard Jay P. Shepard Chief Executive Officer and President